Better efficacy of chemotherapy for small-cell lung cancer (SCLC) has not been convincingly demonstrated despite many investigations examining increased drug
ABSTRACT: Better efficacy of chemotherapy for small-cell lung cancer (SCLC) has not been convincingly demonstrated despite many investigations examining increased drug delivery and enhancement of drug diversity. Improvements in the median- and long-term survival of patients with limited SCLC have been shown, but this change is more closely associated with better integration of chemoradiation than with more effective chemotherapy or radiotherapy components. Recently, a number of new active drugs have been identified for treating patients with SCLC. These drugs include the taxanes, the camptothecins, and gemcitabine. Determining the role of each new agent will require carefully designed and conducted trials like those now in progress. [ONCOLOGY 11(Suppl 9):38-42, 1997]
Small-cell lung cancer (SCLC) is one of the solid tumors most responsive to chemotherapy. Com monly used combination chemotherapy regimens for small-cell lung cancer are usually assembled from five drugs or their analogues. Many permutations and variations of regimens containing cyclophosphamide (Cytoxan) (C), doxorubicin (Adriamycin) (A), etoposide, (VePesid) (E), and cisplatin (Platinol) (P) have been reported and a number of regimens have been regarded as standard. The CAV (cyclophosphamide/Adriamycin/vincristine [Oncovin]), CAVE (CAV plus etoposide), EP (etoposide/Platinol), and alternating CAV/EP have been used most consistently in North America. The standard cycle interval is 3 weeks, and the standard duration of chemotherapy is four to six cycles.
The three most common themes of small-cell lung cancer chemotherapy investigations include increased drug delivery by dose and dose-intensity escalation, enhanced drug diversity by drug addition studies or alternating combinations, and new drug trials. Because of overlapping toxicity, an increase in drug diversity is usually accompanied by a decrease in dose intensity of component drugs.
At the University of British Columbia, we attempted to simultaneously increase dose intensity and drug diversity by changing the cycle interval from 3 weeks to 1 week, alternating myelosuppressive and nonmyelosuppressive weeks of therapy, and administering supportive drugs (steroids and antibiotics). The CODE (cisplatin/Oncovin/doxorubicin/etoposide) regimen was designed to deliver as much cisplatin, more doxorubicin, more vincristine, and more etoposide in 9 weeks than the alternating CAV/EP regimen does in 18 weeks. Patients responding to CODE without residual disease outside the chest after chemotherapy received consolidative thoracic irradiation and prophylactic cranial irradiation.
The population treated had extensive small-cell lung cancer, good performance status, and was less than 66 years of age. A recent update of the data shows a complete response rate of 48% (thoracic
response assigned by chest radiograph rather than computed tomography scan), a median survival of 55 weeks, 2-year survival of 20%, and 5-year survival of 10%. The pilot study suggested that the cure barrier could be broken in extensive small-cell lung cancer, allowing a small but definite proportion of long-term survivors.
Two phase III trials in extensive small-cell lung cancer have been completed comparing CODE with alternating CAV/EP. The study by the Japanese Clinical Oncology Group (JCOG) and the Intergroup (National Cancer Institute of Canada/Southwest Oncology Group [NCIC/SWOG]) trial differed in a number of respects. Differences included age eligibility (patients more than 65 years of age allowed by JCOG but not by NCIC/SWOG), etoposide administration route (all etoposide intravenous by JCOG but oral etoposide given on days 2 and 3 in NCIC/SWOG), cyclophosphamide dose (20% lower in JCOG than in NCIC/SWOG), and radiotherapy policy (thoracic and cranial radiotherapy given to responders in NCIC/SWOG but not routinely by JCOG). An important additional variance between the trials was the type of supportive care administered. JCOG used a granulocyte colony-stimulating factor where-as NCIC/SWOG used steroids (prednisone) and prophylactic antibiotics (cotrimoxazole).
The JCOG study was presented at the 1996 American Society of Clinical Oncology meeting by Furuse et al. Notably, the median age of 64 years in the JCOG trial is older than the median age in the NCIC/SWOG trial (58 years). The granulocyte colony-stimulating factor as used by JCOG appeared to allow delivery of the CODE protocol with good fidelity, as about 85% of patients received all 9 weeks of intended treatment within 10 weeks. Although the overall response rate was somewhat higher with CODE (85.3%) than CAV/EP (76.7%), the difference was not statistically significant, and the proportion of complete responses was about 15% in both arms. The survival curves separate in favor of CODE, but the median (11.9 months for CODE and 10.6 months for CAV/EP) differs by only 6 weeks and the P value was not significant.
Based on the results of the Vancouver pilot study, the treatment-related mortality in the NCIC/SWOG trial was anticipated to be 3% to 4%. Unfortunately, after 220 patients were accrued, the toxic death rate in the CODE arm reached 10%. Clearly, the steroids and antibiotics were insufficient to protect patients from CODE toxicity in the multi-institutional setting. Based on toxicity and an interim analysis, the trial was closed in April of 1996. The median dose intensity and total dose in the CODE arm were the same as intended. The median survival of all patients in the trial was about 1 year, and approximately 20% are alive at 2 years.
Taken together, the preliminary results of these two randomized trials do not demonstrate an advantage to doubling the intensity of multiagent chemotherapy in extensive small-cell lung cancer while maintaining a similar total dose. Although the median survival outcomes for CODE in both phase III trials are similar to those in the Vancouver pilot study (about 1 year), the patient populations overall appear to have better prognostic factors than in many extensive small-cell lung cancer trials. Mature results of both JCOG and NCIC/SWOG studies will be of interest with respect to the percentage of long-term survivors.
Based on the results of randomized trials performed to date, there appears to have been little meaningful progress in improving the effectiveness of chemotherapy for extensive small-cell lung cancer over the past 20 years. The median survival time of 30 to 40 weeks and 2-year survival rates of less than 5% are similar for many combination chemotherapy regimens. The EP regimen has become increasingly popular in both extensive and limited small-cell lung cancer because it has acceptable toxicity and four cycles are considered adequate.
A major factor that has driven EP popularity in limited small-cell lung cancer is the manageable toxicity associated with administration of this regimen with concurrent thoracic irradiation. Early reports[4,5] showed that concurrent EP and thoracic irradiation had less pulmonary, cutaneous, and esophageal toxicity than other chemotherapy regimens, and importantly, both modalities could be administered without dose or treatment delay compromise.
Treatment results for limited small-cell lung cancer have improved over the past 10 years, with median survival times increasing from 14 to 16 months to 20 to 24 months and long-term survival rates increasing from 10% to 20%. This improvement is probably more closely associated with early integrated use of chemoradiation than with better efficacy of the chemotherapy or thoracic irradiation components. Although not all studies of thoracic irradiation timing conclude that early chemoradiation is superior,it is notable that no large study of limited small-cell lung cancer has achieved a state-of-the-art long-term survival of 20% without using early chemoradiation.
As shown in Table 1, many cooperative group trials from around the world were based on the belief that EP was the best chemotherapy regimen for small-cell lung cancer. The trials in Table 1 ask interesting questions, but none compares EP with other chemotherapy regimens. It is curious that, to date, the EP regimen has never been shown to be superior when compared with any other combination chemotherapy regimen in randomized trials of either extensive or limited small-cell lung cancer. It appears that a number of chemotherapy regimens are capable of controlling the chemosensitive component of small-cell lung cancer, and new drugs are needed to deal with the resistant clones that are the principal barriers to progress.
The properties that new drugs should have in order to join or displace standard therapies are considerable. Desirable characteristics of an optimal new agent are shown in Table 2. Because analogues of existing drugs have not demonstrated convincing advantages over the parent compounds in controlled trials, new chemotherapeutic agents must have a different structure with a novel mechanism of action and, more importantly, a novel mechanism of resistance.
A truly interesting drug for small-cell lung cancer should have a monotherapy response rate of ³ 40% to 50% in previously untreated patients, and be able to achieve ³ 10% complete responses. Activity in previously treated patients and evidence of non-cross-resistance with cisplatin and etoposide is crucial. Moreover, because of the increasing acceptance of integrated chemoradiation in limited small-cell lung cancer, it should be possible to administer the new agent concurrently with or adjacent to thoracic irradiation for limited small-cell lung cancer without radiotherapy-chemotherapy interactions that cause serious normal tissue toxicity.
A preferential radiosensitizing effect on the tumor would be a great advantage. Activity should be present over a range of schedules so that dose-response and intensity-response characteristics can be defined. Unless the drug has incredible monotherapy activity, it should combine with existing active drugs in an additive or, preferably, a synergistic fashion.
An obvious corollary is that the new drug must have a toxicity profile that does not preclude administration at full therapeutic doses when combined with the best existing agents or combinations. Cumulative toxicity should not decrease the likelihood of completing the entire treatment program at full dosage on time. The well-being of the increased percentage of long-term survivors must not be endangered by chronic toxicity. The ultimate criterion will be the demonstration that the program incorporating the new drug is unequivocally superior to standard therapy in reproducible randomized comparisons.
The evaluation of new drugs in patients with chemosensitive tumors is an ethical dilemma, and the controversy revolves around the relative merits of studying patients with untreated extensive small-cell lung cancer vs patients with recurrence after previous chemotherapy. Proponents of assessing previously untreated extensive small-cell lung cancer generally use the "window of opportunity" approach, which involves administration of two courses of the new drug, followed by assessment of response. Responders would continue on the new drug, whereas patients with stable disease or any evidence of progression would immediately switch to a conventional salvage regimen like EP.
Demonstration of activity in recurrent small-cell lung cancer is more demanding, as these patients have shown evidence of resistance, and the new agent must be more active than the standard treatment or at least partially non-cross-resistant. Modern trials of new drugs in recurrent small-cell lung cancer distinguish between patient subgroups according to the progression-free interval since previous chemotherapy. Relapse within £ 3 months of prior therapy is sinister; such patients have very refractory disease, and activity of any chemotherapy in this setting is exciting. Relapse with a progression-free interval of > 3 months, and especially > 6 months or > 1 year, is a different matter because such tumors are more chemosensitive. Activity of new agents in this setting is of great interest but investigators must remember that monotherapy with etoposide or combination chemotherapy with EP may demonstrate response rates of 30% or more.
The advocates of treating previously untreated patients will always point to the case of etoposide as an example of a valuable agent that could have been discarded as inactive if only relapsed patients were studied. Although etoposide is very useful in the treatment of small-cell lung cancer, the frustrating lack of progress indicates that we definitely require drugs with non-cross-resistance to EP chemotherapy. Therefore, although trials of new agents in previously untreated extensive small-cell lung cancer are ethical and of scientific interest, demonstrating activity in previously treated patients is more likely to lead to a genuine advance.
Recently, a number of new active drugs have been identified for treating patients with small-cell lung cancer. These agents include the taxanes (paclitaxel [Taxol] and docetaxel [Taxotere]), the camptothecins (irinotecan [Camptosar] and topotecan [Hycamtin]) and gemcitabine [Gemzar]. Table 3 plots some important characteristics for each class.
The taxanes, represented by paclitaxel and the semisynthetic analogue docetaxel, are clearly active in small-cell lung cancer. Two studies of previously untreated extensive small-cell lung cancer by the Eastern Cooperative Oncology Group (ECOG) and the North Central Cancer Treatment Group demonstrated response rates for paclitaxel (250 mg/m2 every 3 weeks by 24-hour infusion) of 53% (17 of 32 patients) and 68% (25 of 37 patients). The median survival times were 6 to 7 months. Smyth et al performed a phase II study of docetaxel 100 mg/m2 as a 1-hour infusion every 3 weeks. Seven (25%) of 28 previously treated patients achieved partial remission.
These topoisomerase I targeting agents include irinotecan (CPT-11) and topotecan. Masuda et al evaluated the activity of CPT-11 against refractory or relapsed small-cell lung cancer. Sixteen heavily pretreated patients received CPT-11 100 mg/m2 as a 90-minute infusion with subsequent doses based on toxicity. Seven patients (44%) had a partial response. This level of activity in previously treated patients is provocative.
Topotecan is a water-soluble camptothecin analogue. The ECOG administered 2.0 mg/m2 of topotecan daily for 5 days on a 3-week cycle to 48 patients with previously untreated extensive small-cell lung cancer. Nineteen (39%) of 48 patients achieved a partial response, and the median survival was 10 months. The authors concluded that the activity of topotecan in extensive small-cell lung cancer observed in this study warranted further investigation in a phase III trial.
Perez-Soler et al assessed topotecan in a patient population that was refractory to etoposide (defined as lack of response to etoposide-containing front-line therapy or progression within 3 months of the last dose of etoposide-containing front-line or second-line therapy). The topotecan schedule was 1.25 mg/m2 daily for 5 days every 21 days. Eleven percent (3 of 32 patients) achieved a partial response and 7% (2 of 32) had a minor response. The overall median survival duration was 20 weeks.
Gemcitabine is a new nucleoside analogue antimetabolite that is interesting because it has activity in a variety of other solid tumors, including non-small cell lung cancer, bladder cancer, breast cancer, and pancreatic cancer. The NCIC evaluated previously untreated extensive small-cell lung cancer patients at a dose of 1,000 to 1,250 mg/m2 once weekly for 3 weeks every 4 weeks. One complete response and six partial responses were observed for an overall response rate of 30% and median survival was 8 months.
The investigation of an active new agent in small-cell lung cancer patients can be performed in a number of ways. Because myelosuppression from EP is moderate in severity, the addition of a new agent to EP is feasible, particularly when cytokine support is added. Substitution of the new drug for etoposide in the EP regimen is attractive when in vitro testing suggests synergism with cisplatin. Following promising phase I and II testing of these designs, the EP regimen would be the appropriate control group in a phase III trial. Depending on the mechanism of action and pharmacology of the new agent, drug addition or substitution studies of other regimens may be appropriate. A different design for a new drug with evidence of non-cross-resistance could be consolidative therapy for patients with limited or extensive small-cell lung cancer after induction with standard therapies.
Investigation of active new agents in multiagent regimens is most advanced for the combination of cisplatin and CPT-11. Fujiwara et al evaluated CPT-11 60 to 80 mg/m2 plus cisplatin 60 mg/m2 in previously untreated small-cell lung cancer, including both limited- and extensive-stage patients. Twenty-two percent of extensive small-cell lung cancer patients had a complete response, 50% had a partial response, and median survival was about 1 year. This result has been sufficiently promising that JCOG is conducting a phase III study of EP vs CPT-11 plus cisplatin in extensive small-cell lung cancer.
In North America, the drugs with the greatest momentum in clinical trials are paclitaxel and topotecan. Kelly et al have demonstrated feasibility and promising activity in preliminary testing of PET (paclitaxel/etoposide/cisplatin). The PET regimen will be further assessed in extensive small-cell lung cancer by the SWOG, which will also study consolidative therapy with carboplatin and paclitaxel in limited small-cell lung cancer patients after induction with chemoradiation including EP. Consolidation with topotecan after EP induction is being considered by other cooperative groups.
A number of new chemotherapeutic agents have shown antitumor activity in small-cell lung cancer including the taxanes (paclitaxel and docetaxel), the camptothecins and gemcitabine. Determining the role of each new agent will require carefully designed and conducted clinical trials such as those now in progress.
1. Ihde DH: Chemotherapy of lung cancer. N Engl J Med 327:1434-1441, 1992.
2. Murray N, Shah A, Osoba D, et al: Intensive weekly chemotherapy for treatment of extensive-stage small-cell lung cancer. J ClinOncol 9:1632-1638, 1991.
3. Furuse K, Kubota K, Nishiwaka Y, et al: Phase III study of dose intensive weekly chemotherapy with recombinant human granulocyte-colony stimulating factor (G-CSF) vs
standard chemotherapy in extensive- stage small-cell lung cancer (abstract 1117). Proc Am Soc Clin Oncol 15:375, 1996.
4. Murray N, Hadzic E, Shah A, et al: Alternating chemotherapy and thoracic irradiation with concurrent cisplatin-etoposide for limited-stage small-cell lung cancer (abstract 835). Proc Am Soc Clin Oncol 3:214, 1984.
5. McCracken JD, Janaki LM, Crowley JJ, et al: Concurrent chemotherapy/radiotherapy for limited small-cell lung carcinoma: A Southwest Oncology Group study. J Clin Oncol 8:892-898, 1990.
6. Murray N, Coy P, Pater J, et al: Importance of timing of thoracic irradiation in the combined- modality treatment of limited-stage small-cell lung cancer. J Clin Oncol 11:336-344, 1993.
7. Perry M, Eaton WL, Propert KJ, et al: Chemotherapy with or without radiation therapy in limited small-cell carcinoma of the lung. N Engl JMed 316:912-918, 1987.
8. Johnson DH, Greco FA, Strupp J, et al: Prolonged administration of oral etoposide in patients with relapsed or refractory small-cell lung cancer: A phase II trial. J Clin Oncol 8:1613-1617, 1990.
9. Vincent M, Kocha W, Kumar T, et al: Neu-
pogen supported chemotherapy in relapsed small- cell lung cancer (abstract 1184). Proc Am Soc Clin Oncol 15:392, 1996.
10. Ettinger DS, Finkelstein DM, Sarma RP, et al: Phase II study of paclitaxel in patients with extensive-stage small-cell lung cancer: An Eastern Cooperative Oncology Group study. J Clin Oncol 13:1430-1435, 1995.
11. Kirshling RJ, Jung SH, Jett JR. et al: A phase II study of Taxol and G-CSF in previously untreated patients with extensive-stage small-cell lung cancer (abstract). Proc Am Soc Clin Oncol 13:329, 1993.
12. Smyth JF, Smith I, Sessa C, et al: Activity of docetaxel (Taxotere) in small-cell lung cancer. Eur J Cancer 30A:1058-1060, 1994.
13. Masuda N, Fukuoka M, Kusunoki Y, et al: CPT 11: A new derivative of camptothecin for the treatment of refractory or relapsed small-cell lung cancer. J Clin Oncol 10:1225-1229, 1992.
14. Schiller JH, KyungMann K, Hutson P, et al: Phase II study of topotecan in patients with extensive-stage small-cell carcinoma of the lung: An Eastern Cooperative Oncology Group trial. J Clin Oncol 14:2345-2352, 1996.
15. Perez-Soler R, Glisson B, Lee JS, et al: Treatment of patients with small-cell lung cancer refractory to etoposide and cisplatin with the topoisomerase I poison topotecan. J Clin Oncol 14:2785-2790, 1996.
16. Cormier Y, Eisenhauer EA, Mudal A, et al: Gemcitabine is an active new agent in previously untreated extensive small-cell lung cancer. Ann Oncol 5:283, 1994.
17. Fujiwara Y, Yamakido M, Fukuoka M, et al: Phase II study of irinotecan (CPT-11) and cisplatin (CDDP) in patients with small-cell lung cancer (abstract). Proc Am Soc Clin Oncol 13:330, 1994.
18. Kelly K, Wood M, Bunn P. A phase I study of cisplatin, etoposide, and paclitaxel (PET) in extensive-stage small-cell lung cancer (abstract 1214). Proc Am Soc Clin Oncol 15:400, 1996.
© 1997 by PRR, Inc. All rights reserved.